BeOne Medicines (BEIGF) Change in Account Payables (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Change in Account Payables data on file, last reported at -$42.2 million in Q1 2026.

• Change in Account Payables for Q1 2026 came in at -$42.2 million, down 33.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $69.2 million (up 58.64% YoY), and the FY2025 annual result was $79.8 million, down 34.29% from the prior year.
• Change in Account Payables fell to -$42.2 million in Q1 2026 per BEIGF's latest filing, from $87.2 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $108.0 million in Q4 2024 and troughed at -$44.1 million in Q2 2024.
• A 5-year average of $10.4 million and a median of -$4.3 million in 2025 frame the typical range for Change in Account Payables.
• On a YoY basis, Change in Account Payables climbed as much as 1192.5% in 2024 and fell as far as 337.19% in 2024.
• A 5-year view of Change in Account Payables shows it stood at -$8.6 million in 2022, then decreased by 15.51% to -$9.9 million in 2023, then soared by 1192.5% to $108.0 million in 2024, then slipped by 19.22% to $87.2 million in 2025, then plunged by 148.37% to -$42.2 million in 2026.
• Business Quant data shows BEIGF's Change in Account Payables at -$42.2 million in Q1 2026, $87.2 million in Q4 2025, and $28.5 million in Q3 2025.